You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report

Article metrics

Article menu
Case report
Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report

 

Online download statistics by month:

Online download statistics by month: January 2021 to March 2026

AbstractFullPdf
Jan 2021367369161
Feb 202118018162
Mar 202113013049
Apr 202110210244
May 202111311349
Jun 202110110136
Jul 202112212229
Aug 2021909023
Sep 2021696927
Oct 2021909047
Nov 2021777735
Dec 2021757527
Jan 2022474930
Feb 2022353535
Mar 2022495025
Apr 2022859127
May 2022878856
Jun 2022525220
Jul 2022676825
Aug 2022797934
Sep 2022676736
Oct 2022555547
Nov 2022555940
Dec 2022333321
Jan 2023283117
Feb 2023606014
Mar 2023585924
Apr 2023424426
May 2023202011
Jun 2023252516
Jul 2023262617
Aug 2023292917
Sep 202320209
Oct 2023262814
Nov 2023414115
Dec 2023707018
Jan 2024323314
Feb 2024383821
Mar 2024363655
Apr 2024212121
May 2024232419
Jun 2024232211
Jul 2024414221
Aug 2024373732
Sep 2024404028
Oct 2024383821
Nov 2024353634
Dec 2024404214
Jan 2025616143
Feb 202512313026
Mar 2025242421
Apr 2025767646
May 2025323220
Jun 2025373720
Jul 2025110
Aug 2025110
Mar 2026110
Total343234701650